global health r&d financing: the experience of non-profit product development organizations...

10
GLOBAL HEALTH R&D FINANCING: THE EXPERIENCE OF NON-PROFIT PRODUCT DEVELOPMENT ORGANIZATIONS Claire Wingfield November 1, 2013 The economic urgency and the pathway to eliminate TB Paris, France

Upload: corbin-tombs

Post on 15-Dec-2015

213 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: GLOBAL HEALTH R&D FINANCING: THE EXPERIENCE OF NON-PROFIT PRODUCT DEVELOPMENT ORGANIZATIONS Claire Wingfield November 1, 2013 The economic urgency and

GLOBAL HEALTH R&D FINANCING: THE EXPERIENCE OF NON-PROFIT PRODUCT DEVELOPMENT ORGANIZATIONS

Claire WingfieldNovember 1, 2013The economic urgency and the pathway to eliminate TBParis, France

Page 2: GLOBAL HEALTH R&D FINANCING: THE EXPERIENCE OF NON-PROFIT PRODUCT DEVELOPMENT ORGANIZATIONS Claire Wingfield November 1, 2013 The economic urgency and

About the Global Health Technologies CoalitionProduct developers… Think tanks…

Advocacy organizations…

Other

Implementing organizations…

Page 3: GLOBAL HEALTH R&D FINANCING: THE EXPERIENCE OF NON-PROFIT PRODUCT DEVELOPMENT ORGANIZATIONS Claire Wingfield November 1, 2013 The economic urgency and

GHTC paper series objectives

The series will inform:•Discussions aimed at improving the coordination and financing of health R&D addressing the needs of LMICs

•The implementation of activities as called for in a resolution passed at the 66th World Health Assembly.

Page 4: GLOBAL HEALTH R&D FINANCING: THE EXPERIENCE OF NON-PROFIT PRODUCT DEVELOPMENT ORGANIZATIONS Claire Wingfield November 1, 2013 The economic urgency and

Non-profit product developers’ role in R&D for low and middle-income countries

Nongovernmental organizations that partner with the public, philanthropic/not-for-profit, and private sectors to develop technologies—diagnostics, drugs, devices, vaccines, and microbicides—targeted at poverty-related and neglected diseases and conditions.

Page 5: GLOBAL HEALTH R&D FINANCING: THE EXPERIENCE OF NON-PROFIT PRODUCT DEVELOPMENT ORGANIZATIONS Claire Wingfield November 1, 2013 The economic urgency and

Challenges and impacts

Donor shifts from unrestricted funding for a portfolio to more narrowly restricted project- or product-

specific funding

• Organizations have less flexibility to shift funds to more promising projects.

• Funding—not science—may drive decision making. • Product developers find it difficult to maintain a portfolio of

products at different stages of development. • Activities are scaled back as overhead funds shrink.

Page 6: GLOBAL HEALTH R&D FINANCING: THE EXPERIENCE OF NON-PROFIT PRODUCT DEVELOPMENT ORGANIZATIONS Claire Wingfield November 1, 2013 The economic urgency and

Challenges and impacts

Small number of major funders

• Competition for smaller amounts of money increases as R&D costs rise and donor funds decrease.

• NPPD’s vulnerability to shifting funder priorities increases.

Page 7: GLOBAL HEALTH R&D FINANCING: THE EXPERIENCE OF NON-PROFIT PRODUCT DEVELOPMENT ORGANIZATIONS Claire Wingfield November 1, 2013 The economic urgency and

Challenges and impacts

Misalignment of funder requirements

• Varying length and timing of donor cycles create significant funding gaps and jeopardize ongoing projects.

• Discordant donor requirements increase burden on and need for specialization of grants management.

Page 8: GLOBAL HEALTH R&D FINANCING: THE EXPERIENCE OF NON-PROFIT PRODUCT DEVELOPMENT ORGANIZATIONS Claire Wingfield November 1, 2013 The economic urgency and

Challenges and impacts

Limited NPPD capacity to identify, cultivate and sustain funding

• Increased staff time and resources must be dedicated to resource mobilization and grants management.

• NPPDs require different business infrastructure and staffing configurations to pursue and manage new funding sources.

Page 9: GLOBAL HEALTH R&D FINANCING: THE EXPERIENCE OF NON-PROFIT PRODUCT DEVELOPMENT ORGANIZATIONS Claire Wingfield November 1, 2013 The economic urgency and

Recommended funding criteria

• Support a portfolio of products at different stages of development.

• Provide sustainable funding commitments.• Support core activities.• Incentivize new investment.

Page 10: GLOBAL HEALTH R&D FINANCING: THE EXPERIENCE OF NON-PROFIT PRODUCT DEVELOPMENT ORGANIZATIONS Claire Wingfield November 1, 2013 The economic urgency and

Thank you

Claire [email protected]

On behalf of Kaitlin [email protected]